Home treatment
 

Keywords :   


Tag: treatment

New Data from Phase 2 Study Evaluating KEYTRUDA (pembrolizumab) for the Treatment of Cancers Deficient in DNA Mismatch Repair Show Durable Responses Across a Range of Cancers

2016-06-05 19:43:00| Merck.com - Research & Development News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced updated findings from a study evaluating KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in patients with advanced cancers characterized as deficient for DNA mismatch repair (MMR). Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Kim Hamilton, 908-740-1863orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: of show data range

 

New Data Evaluating KEYTRUDA (pembrolizumab) in Combination with Chemotherapy for First-Line Treatment of Non-Small Cell Lung Cancer Demonstrate Response Rates Ranging from 48 to 71 Percent

2016-06-04 14:00:00| Merck.com - Research & Development News

Dateline City: KENILWORTH, N.J. Based on Initial Results Presented at 2016 ASCO Annual Meeting, Merck Has Initiated Two Phase 3 Studies KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced findings from an initial proof-of-concept study of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, combined with standard treatments, one with bevacizumab and others without, in non-small cell lung cancer (NSCLC) including chemotherapy in previously untreated patients with NSCLC; the study showed overall response rates (ORR) ranging from 48 to 71 percent, depending on the therapy used. Language: English Contact: MerckMedia Contacts:Pamela Eisele, (267) 305-3558orCourtney Ronaldo, (908) 236-1108orInvestor Contacts:Teri Loxam, (908) 740-1986orJustin Holko, (908) 740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: to data rates response

 
 

AIMPLAS Announces Joint Project for Enhancing Logistics and Waste Treatment in Europe

2016-05-31 16:45:00| Waste Age

AIMPLAS, Spains Plastics Technology Center, has announced a new joint project in Europe. read more

Tags: in project europe treatment

 

Wilhelmsen advocates post-combustion fuel treatment to protect ship's EGB from soot deposition

2016-05-27 01:00:00| Ship Technology

Wilhelmsen Ships Service (WSS) is advising vessel operators of post-combustion fuel treatment to protect the ship's exhaust gas boiler (EGB) from the corrosive effect of soot depositions.

Tags: treatment ships protect fuel

 

Biological Wastewater Treatment: Really Get Bugged

2016-05-24 20:03:00| Chemical Processing

Biological treatment can handle many industrial wastewater streams.

Tags: treatment biological wastewater bugged

 

Sites : [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] next »